Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

primus pharmaceuticals, inc. - genistein (unii: dh2m523p0h) (genistein - unii:dh2m523p0h), zinc glycinate citrate (unii: h3472pj7ya) (zinc cation - unii:13s1s8sf37), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - genistein 27 mg - each fosteum capsule contains 27 mg of genistein aglycone (genistein), derived from a natural source, for a total daily intake of 54 mg. in clinical trials, this level of intake has been shown to increase bone mineral density (bmd). genistein is chemically described as 4',5,7-trihydroxyisoflavone or 5,7-dihydroxy-3-(4-hydroxyphenyl)-4h-1-benzopyran-4-one. it is the aglycone form of the glucoside isoflavone molecule genistin. the empirical formula of genistein is c15 h10 o5 ; its molecular weight is 270.2. the structural formula is: each fosteum capsule contains 20 mg citrated zinc bisglycinate, a glycine amino acid chelate of zinc formed in the presence of citric acid that provides approximately 4 mg of elemental zinc per capsule. zinc is an essential mineral co-factor required by enzymes involved in bone metabolism and has important physiological functions in other tissues throughout the body. elemental zinc has also been shown to have synergistic effects with genistein on bone formation. this zinc bisglycin

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

hameln pharmaceuticals - pentetate zinc trisodium (unii: nxu65ic8pg) (pentetic acid - unii:7a314hqm0i) - injection, solution, concentrate - 200 mg in 1 ml - zn-dtpa is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. none known.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

endo pharmaceuticals inc. - oxymorphone hydrochloride (unii: 5y2ei94nbc) (oxymorphone - unii:9vxa968e0c) - oxymorphone hydrochloride 5 mg - opana er is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve opana er for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - opana er is not indicated as an as-needed (prn) analgesic. opana er is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.3)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.6)] - hypersensitivity t

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - progesterone, quantity: 100 mg - pessary, compressed - excipient ingredients: lactose monohydrate; pregelatinised maize starch; magnesium stearate; povidone; adipic acid; sodium lauryl sulfate; colloidal anhydrous silica; sodium bicarbonate - endometrin pessaries are indicated for luteal support as part of an assisted reproductive technology (art) treatment programme for infertile women.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

endo pharmaceuticals inc. - testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o) - testosterone 75 mg - males androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. - a.primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome; or orchiectomy. - b.hypogonadotropic hypogonadism (congenital or acquired) - gonadotropic lhrh deficiency, or pituitary - hypothalamic injury from tumors, trauma or radiation. if the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sex characteristics. prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testos

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

endo pharmaceuticals inc. - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocaine 50 mg in 1 g - lidoderm is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.

Israel - Tiếng Anh - Ministry of Health

ferring pharmaceuticals ltd - progesterone - vaginal tablets - progesterone 100 mg - progesterone - progesterone - progesterone supplementation or replacement in cases such as treatment of infertile women and ivf.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - milprosa™ is indicated to support embryo implantation and early pregnancy (up to 10 weeks post-embryo transfer) by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women up to and including 34 years of age. limitation of use efficacy in women 35 years of age and older has not been established. milprosa is contraindicated in women with: - known sensitivity to progesterone or any of the ingredients of milprosa [see description (11)] - undiagnosed vaginal bleeding - severe hepatic impairment or disease - known or suspected malignancy of the breast - active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events risk summary milprosa is indicated to support embryo implantation and early pregnancy as part of an assisted reproductive technology treatment program in vitro fertilization (ivf) with or without intracytoplasmic sperm injection (icsi) and embryo transfer for infertile women. maternal risks a

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

endo pharmaceuticals inc. - testosterone undecanoate (unii: h16a5vct9c) (testosterone - unii:3xmk78s47o) - testosterone undecanoate 250 mg in 1 ml - aveed is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. - primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. these men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [fsh], luteinizing hormone [lh]) above the normal range. - hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. these men have low testosterone serum concentrations but have gonadotropins in the normal or low range. aveed should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of pome

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

endo pharmaceuticals inc. - histrelin acetate (unii: qmg7hld1ze) (histrelin - unii:h50h3s3w74) - histrelin acetate 50 mg - supprelin la (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (cpp). children with cpp (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). they also show a significantly advanced bone age that can result in diminished adult height attainment. prior to initiation of treatment a clinical diagnosis of cpp should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (lh) and follicle stimulating hormone (fsh) following stimulation with a gnrh analog, and assessment of bone age versus chronological age. baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adre